The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [ 177 Lu ]Lu‐ DOTA ‐ TATE : A post‐authorisation safety study
Authors:
- Johannes HoflandJHJohannes Hofland
- Chiara Maria GranaCGChiara Maria Grana
- Martin O. WeickertMWMartin O. Weickert
- Andrew R. MooreAMAndrew R. Moore
- Tahir ShahTSTahir Shah
- Vineet PrakashVPVineet Prakash
- Agnieszka Kolasińska‐ĆwikłaAKAgnieszka Kolasińska‐Ćwikła
- Wouter W. de HerderWHWouter W. de Herder
- Francesca SpadaFSFrancesca Spada
- Yuan WuYWYuan Wu
Open Access
- 13 April 2026
- journal article
- research article
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (4) , e70172
Abstract
A post‐authorisation safety study (PASS) was conducted to assess the impact of LysaKare (2.5% Lysine‐Arginine solution) on serum potassium concentrations and its safety/tolerability profile in patients with gastroenteropancreatic neuroendocrine tumours (GEP‐NET) eligible for 177 Lu‐DOTATATE treatment. In a phase IV, multicentre, single‐arm, open‐label PASS, adults with somatostatin receptor‐positive GEP‐NET who were eligible for 177 Lu‐DOTATATE treatment received 1000 mL of LysaKare (monotherapy) intravenously over 4 h. The primary endpoint was the change in serum potassium levels over the course of 24 h. Secondary endpoints included the incidence of LysaKare‐related adverse events (AEs) and changes in laboratory parameters. Forty‐one patients were treated (median age, 57 years; 92.7% White and 7.3% Black; 53.7% male) and 40 completed post‐treatment follow‐up. Mean (standard deviation [SD]) serum potassium was 4.33 (0.397) mmol/L pre‐dose, increasing by 0.60 (0.666) mmol/L after 4 h (time to maximum change, range, 2–24 h) before decreasing to around the pre‐dose level: the mean (SD) increase after 24 h was 0.07 (0.396) mmol/L. Other electrolytes and blood gas components mostly showed transient changes that lasted ~24 h. A general trend of transient metabolic acidosis was also observed based on laboratory values. Serum potassium grade increased from baseline in 41.5% of patients. By comparison, five patients (12.2%) had a treatment‐related AE of hyperkalaemia (grade 3, n = 1); all resolved within 24 h, either without treatment ( n = 3) or following intravenous furosemide ( n = 2). There were no serious AEs and no AEs leading to treatment discontinuation/interruption. This PASS identified no new safety signals attributable to LysaKare. Trial registration: EudraCT, 2019‐004073‐76. Registered 20/08/2020.Keywords
This publication has 17 references indexed in Scilit:
- Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine NeoplasmsEndocrine Reviews, 2020
- Clinical and Research Implications of Serum Versus Plasma Potassium MeasurementsEuropean Journal of Heart Failure, 2018
- Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosisEJNMMI Research, 2018
- Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health SystemHypertension, 2016
- Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapyEJNMMI Research, 2014
- Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapyEJNMMI Research, 2014
- Errors in potassium measurement: A laboratory perspective for the clinicianNorth American Journal of Medical Sciences, 2013
- Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analoguesNephrology Dialysis Transplantation, 2004
- Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginineEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003